Inner Cosmos

Inner Cosmos sits at the intersection of neurotechnology, medical devices, neuroscience, and digital health. Its focus is an implantable neuromodulation device for depression, rather than a general-purpose brain-computer interface: the proposed treatment uses an in-bone implant and stimulation intended to rebalance brain networks. The company describes the Digital Pill as minimally invasive and designed for outpatient placement, with stimulation parameters informed by TMS, ECoG, and DBS approaches. FDA authorization for an early feasibility study and reported human implant procedures distinguish its profile from companies working only on non-invasive stimulation or research-stage software. The available facts also do not show comparative clinical outcomes, commercial adoption, or a regulatory clearance that would establish leadership over other depression-treatment approaches. Its recorded financing totals $11.865 million across four rounds, including a $10 million seed round in 2022, which indicates venture-backed development but does not by itself demonstrate market traction. Its position is therefore best understood as an early clinical-stage medical-device developer with a differentiated implant concept and meaningful evidence still to establish.

Inner Cosmos was founded in 2019 and has built a team listed in the 11–50 employee range, with leadership spanning product, hardware, medical affairs, regulatory work, and investor relations. Its funding history shows a pre-seed round on Jul 30, 2020, seed financing on Mar 30, 2022, another seed round on Oct 25, 2023, and a $1.865 million seed round on Nov 20, 2024. A notable development inflection is the move from device development into human evaluation: reports in September 2023 described implants in two people, and the company has FDA authorization for an early feasibility study. April 2024 coverage brought attention to the device's potential use in depression, while the company describes continued work on individualized stimulation parameters. Its trajectory therefore depends on demonstrating safety and efficacy through further clinical work and translating early feasibility into later-stage evidence.